Company news

ACADIA Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome

June 7, 2023

Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 31, 2023

Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview

May 7, 2023

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

May 1, 2023

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023

April 24, 2023

Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting

April 19, 2023

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome

April 16, 2023

Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

March 9, 2023

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview

February 26, 2023

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

February 13, 2023

Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development

January 8, 2023

Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics

January 2, 2023

Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

December 20, 2022

Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 1, 2022

Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic

October 26, 2022

Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

October 19, 2022

Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors

October 12, 2022

Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed

October 3, 2022

Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA

September 11, 2022

Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 7, 2022

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

August 3, 2022

Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022

July 24, 2022

Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome

July 17, 2022

Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis

June 16, 2022

Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results

May 3, 2022

Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022

May 1, 2022

Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022

April 20, 2022

Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain

April 17, 2022

Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)

March 21, 2022

Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022

March 9, 2022

Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis

March 8, 2022

Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022

March 2, 2022

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

February 27, 2022

Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis

February 15, 2022

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

February 13, 2022

Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022

February 10, 2022

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

January 9, 2022

Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

December 21, 2021

Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)

December 19, 2021

Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer

December 13, 2021

Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome

December 5, 2021

The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia

November 30, 2021

Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms

November 15, 2021

Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results

November 7, 2021

Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021

November 1, 2021

Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial

October 31, 2021

Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021

October 26, 2021

Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

October 24, 2021

Acadia Pharmaceuticals Announces Executive Leadership Change

August 31, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 31 decks. Every deck is listed under its year.